Seres Therapeutics (MCRB) News Today $19.36 +0.56 (+2.98%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$19.32 -0.04 (-0.23%) As of 09/5/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Charles Schwab Investment Management Inc. Sells 31,718 Shares of Seres Therapeutics, Inc. $MCRBSeptember 5 at 3:07 AM | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?August 30, 2025 | marketbeat.comSeres Therapeutics to Present Company Overview at H.C. Wainwright Global Investment Conference on September 8, 2025August 27, 2025 | quiverquant.comQSeres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceAugust 27, 2025 | globenewswire.comSeres Therapeutics’ Earnings Call: Progress Amid ChallengesAugust 16, 2025 | theglobeandmail.comSeres Therapeutics Reports Q2 Results and Leadership ChangeAugust 8, 2025 | theglobeandmail.comSeres (MCRB) Q2 Loss Narrows 34%August 6, 2025 | fool.comSeres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSeres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 6, 2025 | globenewswire.comSeres Therapeutics (MCRB) Expected to Announce Earnings on WednesdayJuly 31, 2025 | marketbeat.comSeres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughJuly 31, 2025 | seekingalpha.comSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025July 22, 2025 | globenewswire.comSBI Securities Co. Ltd. Purchases 48,013 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB)July 20, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Cross Above Fifty Day Moving Average - What's Next?July 5, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average - Here's What HappenedJune 5, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest UpdateJune 3, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Reduce" by BrokeragesMay 29, 2025 | marketbeat.comSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average - Here's WhyMay 19, 2025 | marketbeat.comStockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to HoldMay 11, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.comMay 11, 2025 | marketbeat.comSeres Therapeutics' (MCRB) Neutral Rating Reaffirmed at Chardan CapitalMay 10, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7, 2025 | msn.comSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSeres Therapeutics Q1 2025 Earnings PreviewMay 6, 2025 | msn.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Hold" by BrokeragesMay 5, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50-Day Moving Average - Here's What HappenedMay 4, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.comMay 3, 2025 | marketbeat.comSeres Therapeutics (MCRB) Projected to Post Quarterly Earnings on WednesdayMay 2, 2025 | marketbeat.comSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29, 2025 | globenewswire.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Decrease in Short InterestApril 28, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Hits New 12-Month Low - Here's What HappenedApril 25, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Up 10% - Still a Buy?April 24, 2025 | marketbeat.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comSeres Therapeutics trading halted, volatility trading pauseApril 24, 2025 | markets.businessinsider.comSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025April 23, 2025 | globenewswire.comSeres Therapeutics trading halted, news pendingApril 22, 2025 | markets.businessinsider.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of "Hold" from BrokeragesApril 9, 2025 | marketbeat.comFY2025 Earnings Estimate for MCRB Issued By Chardan CapitalMarch 28, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)March 21, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Price Target Cut to $0.75 by Analysts at The Goldman Sachs GroupMarch 15, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comSeres Therapeutics (MCRB) Gets a Hold from Piper SandlerMarch 14, 2025 | markets.businessinsider.comSeres Therapeutics reports FY24 EPS (81c), consensus (20c)March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finanznachrichten.deSeres Therapeutics announces anticipated upcoming milestonesMarch 13, 2025 | markets.businessinsider.com Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MCRB Media Mentions By Week MCRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼1.760.72▲Average Medical News Sentiment MCRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼12▲MCRB Articles Average Week Get the Latest News and Ratings for MCRB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Seres Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ORGO News Today BCAX News Today RAPP News Today MAZE News Today RZLT News Today RLAY News Today IMTX News Today MRVI News Today KROS News Today TERN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
